Liver disorder
MONDO:0005154A disease involving the liver.
Also known as: disease of liver, disease or disorder of liver, disorder of liver, hepatic disease, hepatic disorder, liver and intrahepatic bile duct disorder, liver disease, liver disease or disorder
3392 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 623 trials in this tab.
-
Booster shot hope: extra hepatitis a vaccine studied for thai kids
⭐️ VACCINE ⭐️ OngoingThis study looks at whether a second, inactivated hepatitis A vaccine can safely boost protection in healthy Thai children and teens who did not develop enough antibodies after a single dose of a live-attenuated hepatitis A vaccine. About 36 participants who took part in an earli…
Phase: PHASE3 • Sponsor: Chiang Mai University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:37 UTC
-
New vaccine aims to train immune system against hepatitis b
⭐️ VACCINE ⭐️ OngoingThis early-stage trial tests a new vaccine called AVX70371, designed to treat chronic hepatitis B by training the immune system to fight the virus. It involves 16 healthy adults aged 18 to 40 to check for safety and immune responses. The study is not yet testing if it works again…
Phase: PHASE1 • Sponsor: AstriVax Therapeutics • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:10 UTC
-
Can a Two-Drug combo outsmart advanced liver cancer?
Disease control OngoingThis early-stage trial is testing whether combining two investigational drugs, livmoniplimab and budigalimab, can safely help people with advanced liver cancer (hepatocellular carcinoma) that has worsened after initial treatment. The study involves about 20 adults in China with a…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 18, 2026 06:00 UTC
-
New drug AU409 enters first human trial for tough liver cancers
Disease control TerminatedThis early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Aug 18, 2026 06:00 UTC
-
New cocktail of drugs shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests a combination of four drugs (gemcitabine, cisplatin, quemliclustat, and zimberelimab) as a first treatment for people with advanced biliary tract cancers, including bile duct cancer. The goal is to see if this mix can slow cancer growth and help people live longe…
Phase: PHASE2 • Sponsor: Nataliya Uboha • Aim: Disease control
Last updated Aug 18, 2026 06:00 UTC
-
New drug aims to reverse liver damage from heavy drinking
Disease control OngoingThis study tests a weekly injection called pemvidutide in 100 adults with alcohol-related liver disease. Participants are overweight or obese and have a history of heavy drinking. The goal is to see if the drug can reduce liver stiffness and scarring over 24 to 48 weeks compared …
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Aug 18, 2026 06:00 UTC
-
Could a blood pressure pill protect your liver from cancer?
Disease control OngoingThis phase II trial tests whether lisinopril, a widely used blood pressure medication, can prevent liver damage from getting worse in people with non-alcoholic fatty liver disease (NAFLD). The study enrolls 45 adults with advanced liver scarring and measures changes in fibrosis m…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to stop liver Cancer's return in High-Risk patients
Disease control OngoingThis study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo therapy aims to boost liver cancer surgery success
Disease control OngoingThis early-phase trial is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with targeted radiation (yttrium-90 microspheres) can safely shrink liver tumors before surgery. About 20 people with resectable hepatocellular carcinoma will receive the com…
Phase: PHASE1 • Sponsor: Jiping Wang, MD, PhD • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
One-Day liver cancer treatment could cut hospital time in half
Disease control OngoingThis study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control OngoingThis study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…
Phase: PHASE1, PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Triple-Drug attack shows promise against tough liver cancer
Disease control OngoingThis study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug bitopertin offers hope for sunlight pain relief in rare blood disorders
Disease control ENROLLING_BY_INVITATIONThis long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…
Phase: PHASE2, PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a custom coaching program slow liver damage?
Disease control OngoingThis study tests whether a personalized, behavior-based program can help people with early liver disease (fatty liver or scarring) manage their condition better than standard care. About 49 adults with risk factors like obesity or diabetes are taking part. The goal is to see if t…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could let Sun-Sensitive patients enjoy the outdoors
Disease control OngoingThis Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …
Phase: PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can calming the immune system save Kids' livers?
Disease control OngoingThis study tests whether two drugs that calm the immune system—high-dose steroids or anti-thymocyte globulin—can help children with sudden, severe liver failure survive without needing a liver transplant. About 163 children aged 1 to 17 will be randomly assigned to receive one of…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a phone app beat fatty liver? new trial tests digital coaching
Disease control OngoingThis trial tests whether a smartphone app and remote diet/exercise coaching can help people with non-alcoholic fatty liver disease lose weight and reduce liver fat. 120 participants will either get standard lifestyle advice or use the app with daily meal tracking, weekly recipe a…
Phase: NA • Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare cancers? drug combo shows promise in early trial
Disease control OngoingThis phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo pill could shrink fatty liver and shed pounds
Disease control OngoingThis study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can an immunotherapy drug keep liver cancer at bay after surgery?
Disease control OngoingThis trial is testing whether toripalimab, an immunotherapy drug, can help prevent liver cancer from returning after surgery. Participants are people with hepatocellular carcinoma who have a high risk of recurrence despite having had the tumor completely removed. Half will receiv…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot aims to silence hepatitis b virus
Disease control OngoingThis study tests an injection called AHB-137 in 20 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the drug can lower or eliminate hepatitis B surface antigen (HBsAg) and viral DNA, potentially leading to a functional cure. Parti…
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could estrogen patch reverse liver damage in postmenopausal women?
Disease control OngoingThis trial tests whether an estradiol patch can reduce liver fat and scarring in postmenopausal women with NASH, a progressive form of fatty liver disease. The study enrolls women aged 45-70 with NASH or fatty liver, giving them either a daily estradiol patch or a placebo for a p…
Phase: PHASE3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cancer drug enzelkitug enters first human trials
Disease control OngoingThis early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy shows promise for tough bile duct cancer
Disease control OngoingThis Phase 2 trial is testing a combination of paclitaxel polymer micelle and immunotherapy for people with advanced biliary tract cancer whose disease has progressed after standard first-line treatment. The study aims to see if this new drug combo can shrink tumors and control t…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Four-Drug cocktail tame inoperable liver cancer?
Disease control OngoingThis trial is testing whether a combination of chemotherapy, immunotherapy, and a targeted therapy can help people with unresectable hepatocellular carcinoma, a type of liver cancer that cannot be removed with surgery. Participants receive a regimen of two chemotherapy drugs (oxa…
Phase: EARLY_PHASE1 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug cocktail shows promise for tough liver cancer
Disease control OngoingThis study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease…
Phase: PHASE2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug candidate BL-M05D1 enters early human trials for tough cancers
Disease control OngoingThis early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase: PHASE1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New cancer drug ABBV-400 enters early human testing
Disease control OngoingThis early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Diabetes drug semaglutide tested as potential treatment for fatty liver disease NASH
Disease control OngoingThis study tests whether semaglutide, a medicine already used for type 2 diabetes, can help people with NASH, a serious liver condition. About 1205 adults with NASH and liver scarring (stage 2 or 3) will receive weekly injections of semaglutide or a placebo for up to 5 years. The…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for rare liver disease: drug shows promise in reducing damage and symptoms
Disease control OngoingThis study tests a new drug called elafibranor in people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants either did not get enough help from or could not take the standard medicine. The goal is to see if elafi…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for liver disease: drug shows promise in reducing damage
Disease control OngoingThis study tests a daily pill called elafibranor in about 18 Japanese adults with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants had not responded well to standard treatment. The main goal is to see if the drug im…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Drug duo targets tough tumors in early trial
Disease control OngoingThis study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New device aims to improve liver transplant outcomes
Disease control OngoingThis study gives continued access to a device that preserves donated livers before transplant. It includes 120 adults on the transplant waiting list. The goal is to collect safety data and check for early signs of liver problems after surgery.
Phase: NA • Sponsor: Organ Recovery Systems, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Supercharged immune cells take on hard-to-treat pancreatic cancer
Disease control TerminatedThis early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for rare bile duct cancer: targeted pill shows promise in Late-Stage trial
Disease control OngoingThis study tests a daily pill called ivosidenib in 220 adults with advanced bile duct cancer that has a specific IDH1 gene mutation and has not responded to prior treatment. The goal is to confirm the drug's safety and effectiveness. Participants take the tablet once daily in 28-…
Phase: PHASE3 • Sponsor: Servier Affaires Médicales • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can two radiation therapies team up to fight liver cancer?
Disease control OngoingThis trial is testing whether combining two types of radiation therapy can safely treat liver cancer that cannot be removed with surgery. The approach uses Y-90 microspheres delivered directly to the liver, followed by targeted external radiation (SBRT). The study also uses PET-C…
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could a vending Machine-Style kiosk curb HIV and overdose deaths in rural america?
Disease control OngoingThis study is testing a special kiosk placed in rural Appalachian Kentucky that provides clean syringes and harm reduction supplies to people who inject drugs. The goal is to see if the kiosk helps reduce the spread of HIV and hepatitis C, and lowers the risk of drug overdose. Ab…
Phase: NA • Sponsor: April M Young • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New immunotherapy combo aims to fight advanced liver cancer
Disease control OngoingThis phase 3 study tests whether adding nofazinlimab (an immunotherapy) to lenvatinib (a standard targeted therapy) helps people with advanced liver cancer live longer. About 534 participants who have not had prior systemic treatment will receive either the combo or a placebo plu…
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can Pre-Surgery drug cocktail stop liver cancer from coming back?
Disease control OngoingThis trial is testing whether giving a combination of drugs before surgery can reduce the risk of liver cancer returning in patients with a single, early-stage tumor that has a high chance of recurrence. Participants will receive either chemotherapy directly into the liver or a t…
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common cholesterol drug help manage a rare liver disease?
Disease control OngoingThis trial is testing the long-term safety of fenofibrate, a drug usually used for high cholesterol, in people with primary biliary cholangitis (PBC), a rare liver disease. The study involves 15 adults who have already completed a previous fenofibrate trial for PBC. Researchers a…
Phase: EARLY_PHASE1 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Freeze-and-Immune combo takes on tough liver cancer
Disease control OngoingThis early-phase trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. Doctors will freeze part of the tumor (cryoablation) and deliver an immune-boosting drug directly into the liver's blood supply. After that, participants receive t…
Phase: PHASE1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase: PHASE2, PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a cancer vaccine prime the body to better fight liver tumors?
Disease control OngoingThis trial tests whether giving a personalized dendritic cell vaccine before a standard liver-directed therapy (TACE) can improve outcomes for people with advanced liver cancer that has not responded to other treatments. The vaccine is made from the patient's own immune cells and…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a menopause-mimicking drug fight fatty liver in endometriosis patients?
Disease control OngoingThis study tests whether goserelin acetate, a drug that temporarily stops menstruation (like a short-term menopause), can reduce liver fat in women with endometriosis who also have fatty liver disease. Researchers will measure liver fat and stiffness using ultrasound in 62 women …
Phase: PHASE4 • Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New targeted pill takes on Hard-to-Treat cancers with IDH mutations
Disease control OngoingThis early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
Disease control OngoingThis phase 2 trial is testing whether adding either ramucirumab (a blood-vessel blocker) or merestinib (a cell-signal blocker) to standard chemotherapy (cisplatin + gemcitabine) can help people with advanced or metastatic biliary tract cancer live longer without their disease wor…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New combo therapy offers hope for Tough-to-Treat colorectal liver cancer
Disease control ENROLLING_BY_INVITATIONThis study tests a combination of the drug abemaciclib with standard chemotherapy (FOLFOX or FOLFIRI) in 16 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a new drug ST316 shrink Hard-to-Treat tumors?
Disease control OngoingThis trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…
Phase: PHASE1 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Cow's first milk could be a lifeline for severe Alcohol-Related hepatitis
Disease control OngoingThis phase 3 trial investigates whether bovine colostrum—the nutrient-rich first milk from cows—can improve survival in people with severe alcohol-associated hepatitis. The condition involves liver inflammation, a leaky gut, and a high risk of infection. Participants receive eith…
Phase: PHASE3 • Sponsor: Dayanand Medical College and Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo shrinks untouchable liver tumors, opens door to surgery
Disease control OngoingThis phase 2 trial tests whether a powerful mix of liver-directed chemotherapy, a targeted drug (lenvatinib), and an immunotherapy (cadonilimab) can shrink liver cancers that were too large or widespread to remove. The goal is to convert these inoperable tumors into ones that can…
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a diabetes drug turn back the biological clock in HIV?
Disease control ENROLLING_BY_INVITATIONThis study investigates whether tirzepatide, a drug used for diabetes and weight loss, can reverse biological aging in people with HIV who are virally suppressed and have obesity. Participants receive tirzepatide for 25 weeks after a diet program. Researchers measure epigenetic a…
Phase: PHASE4 • Sponsor: National Taiwan University Clinical Trial Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immune cell therapy takes on untreatable liver cancer
Disease control OngoingThis study tests an experimental treatment called GKL-006, made from a person's own immune cells (iNKT cells), for liver cancer that cannot be surgically removed. Participants receive GKL-006 injections along with a standard procedure that blocks the tumor's blood supply (TACE). …
Phase: PHASE1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a lighter immunotherapy schedule keep advanced cancers in check?
Disease control OngoingThis trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New targeted therapy aims at Hard-to-Treat bile duct cancers
Disease control OngoingThis phase 2 trial tests an experimental drug called SHR-A1811 in people with advanced biliary tract cancer that has HER2 expression or amplification and has stopped responding to earlier treatments. The drug is an antibody-drug conjugate designed to deliver a chemotherapy-like p…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a diabetes drug reverse liver scarring?
Disease control OngoingThis study tests whether semaglutide, a drug already used for obesity and type 2 diabetes, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD). Participants are adults aged 40 to 80 who are overweight or have type 2 diabetes. The trial will also val…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Texts and tools could help liver transplant patients stay on track
Disease control OngoingThis study tests whether technology and caregiver support can help liver transplant recipients take their medications correctly. Researchers will enroll 360 adults who received a liver transplant within the past 3 months. Participants will use a system called Way to Health, which…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Radiation boosts liver size, paving way for cancer surgery
Disease control OngoingThis study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…
Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail shows promise in liver cancer fight
Disease control OngoingThis study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
Disease control OngoingThis phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…
Phase: PHASE1 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple Hard-to-Treat cancers
Disease control TerminatedThis study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…
Phase: PHASE1, PHASE2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug aims to clear hepatitis b in HIV patients
Disease control OngoingThis study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regul…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to stop liver failure in NASH patients
Disease control OngoingThis phase 3 study tests whether a daily pill called resmetirom can prevent serious liver events like liver failure, need for transplant, or bleeding in people with NASH cirrhosis. About 845 adults with well-compensated cirrhosis will receive either the drug or a placebo. The goa…
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Two-Drug combo aims to cure chronic hepatitis b
Disease control OngoingThis study tests whether giving two experimental drugs in sequence can achieve a functional cure for chronic hepatitis B. Participants are adults with chronic HBV who are already on standard antiviral therapy. They will receive either one of two doses of daplusiran/tomligisiran f…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug aims to shrink liver fat and prevent scarring in fatty liver disease
Disease control OngoingThis Phase II trial tests an injection called DR10624 in 110 adults with fatty liver disease (MASLD) who are at high risk of liver fibrosis (scarring). The study is split into two parts: Part 1 checks if the drug reduces liver fat and fibrosis risk, while Part 2 focuses on safety…
Phase: PHASE2 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill targets bile duct cancer that resists standard treatments
Disease control OngoingThis Phase 3 trial tests an oral drug called tinengotinib against standard treatments chosen by the doctor for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic alteration (FGFR) and has stopped responding to chemotherapy and an FGFR inhibitor…
Phase: PHASE3 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug may reverse liver damage in NASH patients
Disease control OngoingThis study tests a drug called lanifibranor in 1000 adults with NASH (a fatty liver disease) and moderate liver scarring (stages F2 or F3). The goal is to see if the drug can reverse the scarring and reduce liver inflammation over 72 weeks. Participants are randomly assigned to r…
Phase: PHASE3 • Sponsor: Inventiva Pharma • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo takes on tough liver cancers
Disease control OngoingThis study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy duo takes on bile duct cancer in new trial
Disease control TerminatedThis Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a single cell treatment free liver transplant patients from lifelong drugs?
Disease control OngoingThis study tests a personalized cell therapy called QEL-001 in 33 liver transplant recipients. The therapy uses a patient's own cells, modified to train the immune system to accept the donated liver. The goal is to see if it is safe and allows patients to stop taking anti-rejecti…
Phase: PHASE1, PHASE2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial of brelovitug launches
Disease control OngoingThis Phase 3 trial tests a drug called brelovitug (BJT-778) in 80 people with chronic hepatitis delta, a serious liver infection. Participants receive either brelovitug or delayed treatment to see if the drug can lower virus levels and improve liver enzyme counts. The study is re…
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to fight untreatable liver cancer
Disease control OngoingThis phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Pregnant women with hepatitis b: which drug is safer?
Disease control ENROLLING_BY_INVITATIONThis study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the dr…
Phase: PHASE4 • Sponsor: The Third Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Drug duo targets Hard-to-Treat IDH-Mutated tumors
Disease control OngoingThis phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…
Phase: PHASE1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to outsmart biliary cancer
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immunotherapy combo aims to stop liver cancer return after surgery
Disease control OngoingThis phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Epigenetic drug may re-sensitize liver tumors to immunotherapy
Disease control OngoingThis phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to control inoperable liver cancer
Disease control TerminatedThis study tests whether combining the drug regorafenib with a targeted radiation treatment (Y-90 radioembolization) can control liver cancer that cannot be removed by surgery. About 30 adults with this type of liver cancer will receive the combination therapy. The main goals are…
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
Disease control OngoingThis phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a hormone shield bile ducts in transplanted livers?
Disease control ENROLLING_BY_INVITATIONThis trial investigates whether adding secretin—a hormone that helps produce bicarbonate—during machine perfusion of donor livers can restore the protective 'bicarbonate umbrella' in bile ducts. Researchers will treat up to 20 donor livers with secretin while they are kept on a m…
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy hopes to tame advanced cancers
Disease control OngoingThis early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Stomach balloon shows promise for fatty liver – but more proof needed
Disease control ENROLLING_BY_INVITATIONThis study follows 200 people with nonalcoholic fatty liver disease (NAFLD) who receive an intragastric balloon—a device placed in the stomach to help with weight loss. Researchers will track changes in weight, liver enzymes, blood sugar, and liver stiffness for at least one year…
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Surgery vs. diet: which tames diabetes better?
Disease control OngoingThis study compares two types of weight-loss surgery (gastric bypass and gastric banding) with an intensive diet and exercise program for controlling type 2 diabetes in moderately obese adults aged 25 to 55. The goal is to see which approach works best for improving diabetes and …
Phase: NA • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a vaccine tame chronic hepatitis b?
Disease control OngoingThis early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 …
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Cold climate liver cancer study tests new drug combos
Disease control OngoingThis study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…
Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Which catheter delivers better chemo to liver tumors? small trial aims to find out
Disease control OngoingThis trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Immunotherapy combo shows promise in early liver cancer trial
Disease control OngoingThis early-phase trial tests whether giving the immunotherapy drugs nivolumab (Opdivo) with or without relatlimab before and after surgery is safe and feasible for people with liver cancer that can be removed. About 31 participants will receive the drugs before surgery, then cont…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New radioactive beads aim to outperform standard liver cancer therapy
Disease control OngoingThis Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…
Phase: PHASE3 • Sponsor: Chengdu New Radiomedicine Technology Co. LTD. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New triple therapy aims to shrink tough liver tumors
Disease control OngoingThis study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a standard two-drug combination (lenvatinib and a PD-1 inhibitor) helps people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adults will receive either the …
Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Triple threat: drug cocktail and precision radiation take on tough bile duct cancer
Disease control OngoingThis phase II trial tests a combination of two drugs (anlotinib and cadonilimab) plus a special type of radiation (PULSAR) in 26 people with advanced bile duct cancer that has worsened after standard treatment. The goal is to see if this triple therapy can shrink tumors and contr…
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill shows promise for Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…
Phase: PHASE1 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a formula diet reverse fatty liver damage?
Disease control OngoingThis study tests whether a special formula diet can help people with non-alcoholic fatty liver disease (NASH) lose weight and improve liver health. About 20 overweight adults will follow the diet to see if it reduces liver fat and scarring. The goal is to find a safe, effective w…
Phase: NA • Sponsor: West German Center of Diabetes and Health • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Finger-Prick test could speed up hepatitis c treatment
Disease control OngoingThis study tests whether using a dried blood spot test (a simple finger prick) can help people with hepatitis C start treatment faster than the usual method that requires a blood draw. The trial involves 141 participants who work with a peer support program and telemedicine. The …
Phase: NA • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immune cells take on rare bile duct cancer in early trial
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot could shrink enlarged livers and ease pain
Disease control OngoingThis study tests a drug called CAM2029 (octreotide) given as a weekly or every-other-week shot to people with symptomatic polycystic liver disease. The goal is to see if it can shrink the liver and reduce symptoms like belly pain, bloating, and nausea. About 71 adults with an enl…
Phase: PHASE2, PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
Disease control OngoingThis Phase 3 trial tests whether the drug resmetirom (MGL-3196) can reverse liver scarring (fibrosis) and stop NASH from progressing to cirrhosis or liver failure. About 1,759 adults with NASH and liver fibrosis will receive either resmetirom or a placebo daily for up to 54 month…
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for untreatable liver tumors
Disease control OngoingThis phase 2 trial tests a combination of two drugs (donafenib and sintilimab) plus a procedure called TACE in 48 adults with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and control the disease. The study is…
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail of drugs shows promise for bile duct cancer
Disease control OngoingThis study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a simple wash during surgery extend lives of pancreatic cancer patients?
Disease control OngoingThis study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail aims to make liver cancer operable
Disease control TerminatedThis study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New blood filter shows promise for liver failure patients
Disease control OngoingThis study tests a blood-filtering treatment called DPMAS for people with severe liver failure. The goal is to see if it can lower the risk of death or worsening disease within weeks. About 1300 adults with chronic liver disease and high bilirubin levels are taking part. Research…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill shows promise for fatty liver in major trial
Disease control OngoingThis study tests a daily pill called resmetirom in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it safely reduces liver fat and cholesterol over 52 weeks. About 810 adults who completed earlier related studies are taking part. This is a long-term t…
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Online diet program shows promise for fatty liver
Disease control OngoingThis study tested whether a 12-week online Mediterranean diet program could reduce liver fat in people with a type of fatty liver disease (MASLD). 78 adults followed either the diet program or received standard advice. The goal was to see if the diet could improve liver health an…
Phase: NA • Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a simple antiviral stop hepatitis b from waking up in lymphoma patients?
Disease control OngoingThis study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to shrink GI cancers before surgery
Disease control OngoingThis phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New registry monitors liver transplant device in thousands of patients
Disease control ENROLLING_BY_INVITATIONThis study is a registry that collects information from up to 5,000 people who received a liver transplant after the donated liver was treated with the VitaSmart HOPE system. The device keeps the liver cool and oxygenated before transplant. The goal is to see how well the device …
Sponsor: Bridge to Life Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise for untreatable liver cancer
Disease control OngoingThis early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior syst…
Phase: PHASE1 • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New imaging tech aims to sharpen liver cancer radiation
Disease control OngoingThis study looks at whether a special imaging technique called KIM can help doctors deliver radiation more accurately to liver tumors. About 32 adults with liver cancer who cannot have surgery or a transplant will receive radiation with and without KIM tracking. The goal is to se…
Phase: NA • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Smaller liver grafts could revolutionize transplant safety
Disease control ENROLLING_BY_INVITATIONThis study looks at a new way to do liver transplants for people with severe portal hypertension. Instead of using a full-sized liver, doctors will use a smaller piece (small-for-size graft) in an auxiliary transplant, leaving part of the original liver in place. The goal is to s…
Sponsor: Zhi-Jun Zhu • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could nopal, cacao, and cricket help fatty liver?
Disease control ENROLLING_BY_INVITATIONThis study tests a supplement made from nopal, cacao, and cricket in 60 adults with fatty liver disease (MASLD). Participants take the supplement or a placebo daily for 3 months, along with dietary guidance. The goal is to see if the supplement reduces liver fat, improves health …
Phase: NA • Sponsor: University of Guadalajara • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for kids with rare liver tumors: tailored therapy trial shows promise
Disease control OngoingThis study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The app…
Phase: PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for bile duct cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called olaparib in 32 people with advanced bile duct cancer that has spread and has certain DNA repair gene mutations. Olaparib works by blocking enzymes that cancer cells need to grow. The main goal is to see how many patients are alive without their canc…
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug IBI362 takes on semaglutide in fatty liver showdown
Disease control OngoingThis study tests whether a new weekly injection called IBI362 works better than the existing drug semaglutide for weight loss and reducing liver fat in overweight or obese Chinese adults with metabolic dysfunction-associated fatty liver disease (MAFLD). About 479 participants wil…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Hope for liver disease: new drug trial targets PBC symptoms
Disease control OngoingThis study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug is safe and helps control the disease. About 102 adults who completed a previous PBC study will take the drug and be mon…
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could hepatitis c positive lungs save lives? pilot study explores new transplant option
Disease control OngoingThis study tests whether lungs from donors with hepatitis C can be safely transplanted into people without the virus. The lungs are treated with a special machine to try to reduce the virus. If the recipient gets infected, they will be treated with standard antiviral medication. …
Phase: EARLY_PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Liver transplant bleeding study pulled before starting
Disease control TerminatedThis study was designed to see if a new concentrated fibrinogen product works better than the standard one for controlling bleeding in liver transplant patients. It planned to enroll adults having a cadaveric liver transplant who were at risk for low fibrinogen levels. However, t…
Phase: PHASE4 • Sponsor: Ezeldeen Abuelkasem • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Universal CAR-T therapy targets Hard-to-Treat liver and lung cancers
Disease control TerminatedThis early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…
Phase: PHASE2, PHASE3 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug cocktail aims to shrink Hard-to-Treat liver and bile duct tumors
Disease control OngoingThis phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation can shrink tumors in people with advanced liver or bile duct cancer. The study enrolled 37 adults whose cancer had spread or could not be removed by surgery. The goal i…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo tackles liver cancer after standard drug fails
Disease control OngoingThis phase 2 trial is testing whether adding doxorubicin to sorafenib can help people with advanced liver cancer whose disease has progressed while on sorafenib alone. The study enrolls 30 adults with confirmed liver cancer and Child-Pugh A cirrhosis or no cirrhosis. Researchers …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could 'Peacekeeper' cells free liver transplant patients from lifelong drugs?
Disease control OngoingThis early-phase trial tests whether infusing specially grown donor-specific regulatory T cells (Tregs) can allow liver transplant recipients to safely reduce or stop their anti-rejection medications. Nine participants will receive a single dose of these cells and be monitored fo…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for PBC patients: Long-Term safety trial of seladelpar underway
Disease control OngoingThis study is testing the long-term safety of a drug called seladelpar in people with primary biliary cholangitis (PBC), a chronic liver disease. About 340 adults who have taken seladelpar before will receive either 5 mg or 10 mg daily for several years. Researchers will monitor …
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Liver-Directed chemo shows promise for eye cancer metastases
Disease control OngoingThis phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Water pill could boost liver cancer treatment
Disease control OngoingThis early-phase trial tests whether adding a common water pill (bumetanide) to a standard procedure that blocks blood flow to liver tumors is safe and might help slow tumor growth. About 30 people with liver cancer that cannot be removed by surgery will take part. The study will…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New shot aims to cure hepatitis b without daily pills
Disease control OngoingThis phase 3 trial tests an experimental drug called AHB-137 in 577 adults with HBeAg-negative chronic hepatitis B who are already on standard antiviral pills. Participants receive weekly injections of AHB-137 or a placebo for a set period, then stop all hepatitis B treatment. Th…
Phase: PHASE3 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for transplant patients with hepatitis b: safer drug switch under study
Disease control OngoingThis study looks at switching kidney or liver transplant patients with chronic hepatitis B to a drug called tenofovir alafenamide (TAF). The goal is to see if TAF is safer for the kidneys, controls the virus well, and is easier for patients to stick with. The study involves 52 ad…
Phase: PHASE4 • Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a targeted drug beat standard care for shock in liver patients?
Disease control OngoingThis study tests whether a drug called Angiotensin II can raise blood pressure more effectively than standard medications in people with liver cirrhosis who have septic shock. Researchers will measure how well the heart and blood vessels work together over 24 hours. The trial inv…
Phase: EARLY_PHASE1 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Reishi mushroom tested as fatty liver treatment in new study
Disease control ENROLLING_BY_INVITATIONThis study tests whether Ganoderma lucidum (a type of mushroom) can improve antioxidant levels and liver health in people with Metabolic Associated Fatty Liver Disease (MAFLD). Forty adults aged 35-49 with early-stage fatty liver will take the mushroom supplement. Researchers wil…
Phase: NA • Sponsor: University of Agriculture, Peshawar • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Second chance: new combo aims to clear hepatitis c after relapse
Disease control OngoingThis study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Rese…
Sponsor: Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Common heart drug may stop deadly bleeding in liver patients
Disease control OngoingThis study tests whether beta-blockers, a type of blood pressure medicine, can reduce the risk of bleeding from small varices in people with cirrhosis and portal hypertension. About 763 adults with small varices will receive either beta-blockers or a placebo for up to 3 years. Th…
Phase: PHASE4 • Sponsor: King's College Hospital NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
App-tastic hope: smartphone tool aims to shrink fatty livers
Disease control OngoingThis study tests whether a smartphone app can help Chinese adults with non-alcoholic fatty liver disease (NAFLD) lose weight over 12 months. Weight loss is currently the only proven way to reverse liver fat and prevent serious complications. The trial will enroll 260 participants…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat liver cancer
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Resea…
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a common diabetes drug help drain dangerous belly fluid?
Disease control OngoingThis study looks at whether SGLT2 inhibitors, a type of diabetes medication, can help control ascites (fluid buildup in the belly) in people with liver cirrhosis and type 2 diabetes. Researchers will compare 40 patients who add the drug to their usual treatment against those who …
Sponsor: University of Palermo • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental combo targets tough liver cancer
Disease control OngoingThis early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The …
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New immunotherapy combo shows promise for advanced liver cancer
Disease control OngoingThis study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for liver cancer patients resistant to standard therapy
Disease control OngoingThis study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for hepatitis b: Real-World trial of pradefovir underway
Disease control OngoingThis study is testing a drug called pradefovir mesylate in 400 adults with chronic hepatitis B. The goal is to see how well it lowers the virus and how safe it is in everyday medical practice, not just in a strict research setting. Participants are being followed for up to 65 wee…
Sponsor: Juan Li • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Immunotherapy combo may boost liver cancer ablation outcomes
Disease control OngoingThis phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stomach stitching without surgery: can it reverse fatty liver?
Disease control OngoingThis study looks at whether a non-surgical stomach-reducing procedure called endoscopic sleeve gastroplasty (ESG) can help obese people with nonalcoholic fatty liver disease lose weight and improve liver health. Researchers will measure changes in liver fat and stiffness, as well…
Sponsor: West Virginia University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Soybean oil shows promise for fatty liver – no weight loss needed
Disease control OngoingThis study looks at whether eating three soybean-oil-based foods each day for 16 weeks can lower fat buildup in the liver and belly fat in people with nonalcoholic fatty liver disease. Participants keep their usual weight during the trial. The goal is to see if changing the type …
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy hepatitis b drug showdown: which is safer for mom and baby?
Disease control ENROLLING_BY_INVITATIONThis study tests two antiviral medications, TAF and TDF, in 200 pregnant women with chronic hepatitis B. The goal is to see which drug better prevents passing the virus to the baby and causes fewer birth defects or side effects. Participants take the drug daily during pregnancy a…
Phase: PHASE4 • Sponsor: The Third Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Custom-Made DNA vaccine takes on advanced liver cancer
Disease control OngoingThis study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…
Phase: PHASE1, PHASE2 • Sponsor: Geneos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Peer support after prison may boost hepatitis c care
Disease control OngoingThis study tests whether peer mentors—people with similar experiences—can help individuals recently released from jail or prison get connected to Hepatitis C care and stay in treatment. About 80 participants will either receive a peer mentor or standard referral. The goal is to s…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental combo aims to rally immune system against tough liver cancer
Disease control OngoingThis early-phase trial tests whether adding an immune-boosting drug called IRX-2 to standard immunotherapy (nivolumab) and a low dose of chemotherapy (cyclophosphamide) is safe and tolerable for people with advanced liver cancer that has come back or spread. Only 8 participants a…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can a keto diet help obese patients with advanced liver disease?
Disease control OngoingThis study tests whether a monitored ketogenic diet is safe and effective for weight loss in 40 obese adults with compensated NASH cirrhosis. Participants are randomly assigned to either a ketogenic diet or standard dietary advice for 16 weeks. The main goals are to check for liv…
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Cash for sobriety: new trial aims to keep transplant patients off alcohol
Disease control OngoingThis study tests a behavioral program called contingency management for people who have had a liver transplant due to alcohol-related liver disease and have started drinking again. Participants get rewards like gift cards for staying alcohol-free, measured by urine and blood test…
Phase: NA • Sponsor: Arpan A. Patel, MD • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Pregnant women with hepatitis c get new hope from 12-Week drug trial
Disease control OngoingThis study tests a 12-week course of the drug Sofosbuvir/Velpatasvir in about 100 pregnant women with chronic hepatitis C. The goal is to see if the treatment can cure the virus and whether it affects the timing of delivery. Mothers are followed for 12 weeks after treatment, and …
Phase: PHASE4 • Sponsor: Catherine Anne Chappell • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a weekly shot help obese teens avoid diabetes and fatty liver?
Disease control OngoingThis study tests whether semaglutide (Wegovy), a once-weekly injection, can preserve the pancreas's ability to produce insulin and reduce liver fat in 60 obese youth with prediabetes or early type 2 diabetes and fatty liver disease. Participants receive either semaglutide or a pl…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Stem cell injection aims to prevent deadly liver complication
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests whether injecting special liver-like cells into the abdominal muscle can help prevent or treat Small-for-Size syndrome, a serious complication that can occur after partial liver surgery. The study involves 12 patients and focuses mainly on safety, che…
Phase: EARLY_PHASE1 • Sponsor: Zhi-Jun Zhu • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Gut health fix for HIV fatty liver? early trial tests probiotics
Disease control OngoingThis early-phase study tests whether taking prebiotic fiber and probiotics can improve fatty liver disease in people with HIV. Researchers believe changes in gut bacteria may contribute to liver problems. The trial involves 63 participants and measures liver fat and gut health ma…
Phase: EARLY_PHASE1 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New oil could boost liver cancer treatment
Disease control TerminatedThis study tests a new oil called T-ACE Oil, mixed with a chemotherapy drug, for people with liver cancer that cannot be removed by surgery. The oil is injected directly into the liver's blood vessels to block them and deliver chemo to the tumor. The trial aims to see if it is sa…
Phase: PHASE1, PHASE2 • Sponsor: T-ACE Medical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New electrode aims to safely burn away small liver tumors
Disease control OngoingThis study tests a special electrode for radiofrequency ablation in people with small liver cancers (3 cm or less). The electrode monitors temperature and can adjust its tip to match tumor shape, aiming to destroy the tumor while protecting nearby organs. Researchers will track w…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a lung drug save kidneys in liver patients?
Disease control OngoingThis study tests whether ambrisentan, a drug approved for lung blood pressure, can help patients with hepatorenal syndrome—a serious kidney problem that can occur in advanced liver cirrhosis. About 54 hospitalized adults will receive either ambrisentan or the standard drug terlip…
Phase: PHASE2 • Sponsor: Noorik Biopharmaceuticals AG • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise for liver cancer in hepatitis b patients
Disease control OngoingThis study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…
Phase: NA • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Pig liver keeps patient alive in World-First Bridge-to-Transplant trial
Disease control OngoingThis early-phase trial tests whether a gene-edited pig liver, used outside the body like a dialysis machine, can temporarily support liver function in one person with severe liver failure. The goal is to keep the patient stable until a human liver transplant becomes available. Pa…
Phase: EARLY_PHASE1 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control OngoingThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy shows promise in battle against advanced liver cancer
Disease control OngoingThis study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help people with advanced liver cancer live longer than current standard treatments. About 732 participants who have not had prior systemic therapy will be randomly assigned to receiv…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immune drugs given before surgery show promise against multiple cancers
Disease control OngoingThis phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a popular diabetes drug help liver transplant patients control blood sugar?
Disease control ENROLLING_BY_INVITATIONThis study compares two diabetes medications, semaglutide and sitagliptin, in 58 adults who have had a liver transplant and have poorly controlled diabetes. The goal is to see which drug better lowers blood sugar and body weight. Participants will take the study drug daily for th…
Phase: PHASE4 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to unleash immune system on liver cancer
Disease control OngoingThis phase 2 trial is testing whether two immunotherapy drugs, cobolimab and dostarlimab, can help people with advanced liver cancer. The drugs work by helping the immune system recognize and attack cancer cells. The study involves 42 adults whose liver cancer has spread or canno…
Phase: PHASE2 • Sponsor: University of Hawaii • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New radiation approach targets liver tumors without surgery
Disease control OngoingThis study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New cocktail targets HER2-Positive bile duct cancer in small trial
Disease control OngoingThis phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New dosing strategy aims to make liver cancer drug easier to tolerate
Disease control OngoingThis phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to se…
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Chemo-Oil combo shows promise for liver cancer patients who Can't have surgery
Disease control OngoingThis study tests a new, stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in people who cannot or choose not to have surgery. The treatment combines TACE (a procedure that blocks the tumor's blood supply and delivers chemo directly) with he…
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a Step-by-Step program help latinos beat fatty liver?
Disease control OngoingThis study looks at whether a 26-week behavioral weight loss program called 'Paso a Paso' is practical for Mexican and Central American adults with fatty liver disease and overweight. Researchers will track attendance, weight loss, liver stiffness, and diet changes in 50 particip…
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cell injection aims to repair damaged livers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests a single injection of HCL001 cells in 39 people with decompensated cirrhosis, a severe form of liver disease. The study aims to check safety and see if the treatment can improve liver function. Participants receive one of three dose levels, and resear…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Huicun Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple drug cut dangerous blood pressure swings in liver transplants?
Disease control OngoingThis study tests whether a drug called Angiotensin II can help control blood pressure during liver transplant surgery, reducing the need for other strong blood pressure medicines. It involves 50 adults with severe liver disease who are receiving a liver from a deceased donor. The…
Phase: PHASE2, PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
AI coach for transplant patients: will it cut hospital stays?
Disease control ENROLLING_BY_INVITATIONThis study tests a smartphone app that uses artificial intelligence to help liver transplant recipients manage their health after surgery. Researchers will track whether the app improves patients' confidence, daily self-care, and quality of life, and reduces emergency visits or i…
Phase: NA • Sponsor: Chang Gung University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for liver cancer patients: which procedure best prevents dangerous rebleeding?
Disease control OngoingThis study looks at 70 people with liver cancer who had bleeding from enlarged veins in the esophagus. It compares two procedures—an ultrasound-guided injection of a glue-like substance versus a banding technique—to see which better prevents future bleeding. The goal is to find t…
Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a cancer drug help cure hepatitis b? new trial launches
Disease control OngoingThis pilot study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg), a key step toward a functional cure. The trial will enroll 45 adults wh…
Phase: NA • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill for fatty liver disease enters first human tests
Disease control OngoingThis early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL-C (bad cholesterol), a risk factor for MASH (a serious liver disease). The main goal is to check if the drug is safe and how the body processes it. 80 participants will receive …
Phase: PHASE1 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Ancient herb takes on fatty liver: new trial begins
Disease control ENROLLING_BY_INVITATIONThis phase 3 trial tests whether a herbal extract called Picroliv can help people with non-alcoholic fatty liver disease (NAFLD). 170 adults with mild to moderate NAFLD will take either Picroliv or a placebo twice daily for 24 weeks, alongside standard lifestyle advice. The main …
Phase: NA • Sponsor: Bioagile Therapeutics Pvt. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill targets rare bile duct cancer mutation in late-stage trial
Disease control OngoingThis study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingThis phase 2 study tests a new drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants receive either CS0159 or a placebo for 12 weeks, followed by 40 weeks of open-label treatment. The goal is to see if CS0159 is safe and can…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cancer drug YL201 enters human testing for advanced tumors
Disease control OngoingThis study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New RNA drug aims to reverse liver damage in NASH patients
Disease control OngoingThis phase 2 trial is testing an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to cirrhosis. VSA006 is an RNA-based drug designed to lower a liver protein linked to disease progression. The study compares VSA006 inject…
Phase: PHASE2 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Liquid diet could shrink fatty liver without surgery
Disease control OngoingThis study looks at whether a very low-calorie diet (800-960 calories per day) can reduce fat and scarring in the liver for people with obesity and non-alcoholic fatty liver disease (NAFLD). Twenty participants will follow either the low-calorie diet or a standard lower-calorie d…
Phase: NA • Sponsor: University of Iowa • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Supercharged immune cells take on tough cancers in early human test
Disease control OngoingThis early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in th…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to slow liver and lung cancers
Disease control OngoingThis phase 2 trial is testing the drugs atezolizumab and bevacizumab in 36 people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control and to study changes in tumors and blood before an…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could an immunotherapy drug tame liver cancer in hepatitis b patients?
Disease control OngoingThis phase 2 trial is testing the drug pembrolizumab in 30 people with advanced liver cancer linked to hepatitis B. Participants receive pembrolizumab every 3 weeks, and researchers will check how the tumors respond and how the immune system changes. The goal is to see if this im…
Phase: PHASE2 • Sponsor: CCTU • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for liver cancer patients who stop responding to immunotherapy?
Disease control OngoingThis phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug E7386 tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Immunotherapy duo takes on rare cancers
Disease control OngoingThis Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…
Phase: PHASE2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can stem cells repair a scarred liver? new trial hopes so
Disease control ENROLLING_BY_INVITATIONThis early-stage trial is testing whether stem cells from donated umbilical cords can help people with liver cirrhosis caused by hepatitis B. The study will give 12 patients an intravenous infusion of these stem cells and monitor their liver function, Child-Pugh score, and MELD s…
Phase: PHASE1, PHASE2 • Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for liver cancer: drug combo trial launches
Disease control ENROLLING_BY_INVITATIONThis phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Par…
Phase: PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental pill plus keytruda takes on tough cancers
Disease control OngoingThis study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…
Phase: PHASE1, PHASE2 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for hepatitis b patients: switching to TAF after relapse
Disease control OngoingThis study looks at 260 chronic hepatitis B patients who stopped their antiviral medication and then had a flare-up. They are switched to a drug called tenofovir alafenamide (TAF) to see if it can control the virus and improve liver health. The goal is to measure how many patient…
Phase: PHASE4 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug targets bile duct cancer in small trial
Disease control OngoingThis phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers…
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study aims to help cancer survivors manage other health problems
Disease control OngoingThis study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 part…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug aramchol aims to reverse fatty liver damage in phase 3 trial
Disease control TerminatedThis study tests a drug called Aramchol for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. About 150 adults with NASH and liver scarring (stages 1-3) will take Aramchol or a placebo for up to 72 weeks. The goal is to see …
Phase: PHASE3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cocktail of drugs shows promise against tough bile duct cancer
Disease control OngoingThis phase 2 trial tests a combination of immunotherapy (camrelizumab), a targeted therapy (apatinib), and chemotherapy (gemcitabine and oxaliplatin) given before and after surgery for 30 people with advanced biliary tract cancer. The goal is to see if this approach can shrink tu…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for tough liver cancers? early trial tests Two-Drug punch
Disease control OngoingThis early-stage trial is testing a combination of two drugs—cadonilimab and regorafenib—in 30 adults with advanced liver cancer that has worsened after at least one prior therapy. The goal is to see if the combo can shrink tumors or slow the disease, while also checking for side…
Phase: PHASE1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill aims to tackle fatty liver and diabetes at once
Disease control OngoingThis phase 2 trial tests an oral drug called MN-001 (tipelukast) in 40 adults with non-alcoholic fatty liver disease, type 2 diabetes, and high triglycerides. Participants take either the drug or a placebo daily for 24 weeks. The study measures changes in liver fat and blood fat …
Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingThis study tests a combination of two drugs (toripalimab and bevacizumab) alongside three types of artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the ca…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy hopes to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…
Phase: PHASE1, PHASE2 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for rare liver infection: RBD1016 trial underway
Disease control OngoingThis study tests an experimental drug called RBD1016 in 14 adults with chronic hepatitis D, a serious liver infection. The main goal is to see if the drug can lower the amount of virus in the blood over 60 weeks. Participants receive either RBD1016 or a placebo and visit the clin…
Phase: PHASE2 • Sponsor: Ribocure Pharmaceuticals AB • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Radioactive beads offer new hope for inoperable liver cancer
Disease control OngoingThis study tests a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and control…
Phase: NA • Sponsor: Sirtex Medical • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for kids with hepatitis b: drug trial shows promise
Disease control OngoingThis study tested an antiviral drug called tenofovir in children aged 2 to 12 with chronic hepatitis B. The goal was to see if the drug could lower the amount of virus in their blood compared to a placebo. The trial involved 90 children and measured safety and effectiveness over …
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Diabetes drug could help stop liver damage in hepatitis b patients
Disease control OngoingThis study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 participants with moderate to severe liver scarring will take either empagliflozin or a placebo daily for three years. T…
Phase: PHASE4 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Cancer pill may boost ablation success in aggressive liver tumors
Disease control OngoingThis study tests whether the targeted drug lenvatinib, given before and after a standard tumor-burning procedure (ablation), can help prevent liver cancer from returning in patients with aggressive tumors. About 32 adults with high-risk features (like high AFP levels or infiltrat…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to stop liver cancer recurrence in transplant patients
Disease control ENROLLING_BY_INVITATIONThis study tests whether the drug everolimus can lower the risk of liver cancer coming back after a liver transplant in patients with high-risk hepatocellular carcinoma. About 336 adults who have just received a transplant will be randomly assigned to take everolimus plus tacroli…
Phase: PHASE4 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy may help liver cancer patients bridge to transplant
Disease control OngoingThis pilot trial is testing whether adding stereotactic body radiation therapy (SBRT) to the standard transarterial chemoembolization (TACE) can better control liver cancer in patients waiting for a liver transplant. About 40 patients will be enrolled to see if the combination im…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for bile duct cancer: targeted chemo combo shows promise in early trial
Disease control OngoingThis Phase 2 study is testing a combination of three drugs—nanoliposomal irinotecan, fluorouracil, and leucovorin—in 48 adults with advanced biliary tract cancer that has progressed after initial chemotherapy. The main goal is to see if the treatment can stop the cancer from grow…
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New combo therapy targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests whether combining two drugs—regorafenib (a targeted therapy) and durvalumab (an immunotherapy)—can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive both drugs to see if the combination …
Phase: PHASE1, PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug SH006 tested in patients with advanced solid tumors
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…
Phase: PHASE1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Liver cirrhosis patients: new drug may cut rebleeding risk
Disease control ENROLLING_BY_INVITATIONThis study tests whether carvedilol, a newer blood pressure drug, works better than the standard drug propranolol for preventing another bleeding episode in people with liver cirrhosis who have already had variceal bleeding. Both drugs are given alongside a procedure to tie off s…
Phase: PHASE4 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for liver cancer with vein invasion: triple therapy tested in phase 3 trial
Disease control OngoingThis study tests whether adding a liver-directed chemotherapy infusion to a two-drug immunotherapy regimen can help people with advanced liver cancer that has spread to the main vein of the liver. About 214 participants will be randomly assigned to receive either the triple thera…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could a statin tame fatty liver disease? new trial seeks answers
Disease control OngoingThis study tests whether atorvastatin (Lipitor), a widely used cholesterol medication, can safely improve liver damage in people with NASH, a serious fatty liver disease. About 70 adults with confirmed NASH and liver scarring will receive either the drug or a placebo. The goal is…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo aims to fight bile duct cancer
Disease control OngoingThis Phase 3 trial is testing whether a new immunotherapy drug called AK112, when combined with standard chemotherapy, works better than another immunotherapy (durvalumab) plus the same chemo for people with advanced bile duct cancer. The study includes 682 participants who have …
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo attack: surgery and drugs take on tough liver cancer
Disease control OngoingThis phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays …
Phase: PHASE3 • Sponsor: Jia Fan • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Sound waves zapping liver tumors? new device tested in 24 patients
Disease control OngoingThis trial tests a device called HistoSonics that uses focused ultrasound (sound waves) to mechanically destroy liver tumors without heat or needles. It includes 24 adults with liver cancer or tumors that spread to the liver. The main goals are to see if the device can fully cove…
Phase: NA • Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New study aims to catch fatty liver early in kids with simple waist measurement
Disease control OngoingThis study focuses on children aged 7 to 11 with a high waist-to-height ratio, a sign of possible fatty liver disease (MASLD). Researchers will test a simple screening method and a lifestyle program involving school, clinic, family, and community support. The goal is to improve e…
Phase: NA • Sponsor: Ningbo No. 1 Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer cocktail aims to rev up immune system against tumors
Disease control OngoingThis early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a herbal extract keep liver cancer away after surgery?
Disease control OngoingThis study tests whether icaritin soft capsules, taken daily for up to a year, can help prevent liver cancer from coming back in patients who had surgery to remove their tumor. Twenty adults with high-risk features for recurrence will take the capsules twice a day. The main goal …
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a cholesterol drug help fight a rare liver disease?
Disease control OngoingThis study tests whether adding fenofibrate (a drug used for high cholesterol) to standard treatment with ursodeoxycholic acid can improve liver health in people with primary biliary cholangitis (PBC), a rare autoimmune liver disease. About 184 adults with PBC will receive either…
Phase: PHASE2, PHASE3 • Sponsor: Han Ying • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo aims to wipe out hepatitis c in Hard-to-Treat patients
Disease control OngoingThis study follows 30 adults with chronic hepatitis C (genotype 3) and mild to moderate liver fibrosis who are taking ravidasvir and sofosbuvir as part of their regular care. Researchers will check if the virus is undetectable 12 weeks after treatment ends (SVR12). The goal is to…
Sponsor: Center of target therapy • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug cocktail aims to stop liver cancer recurrence
Disease control OngoingThis phase 3 trial tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—can prevent liver cancer from coming back in patients at high risk of recurrence after curative surgery or ablation. About 687 participants will receive eithe…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for advanced liver cancer: experimental drug takes on standard therapy
Disease control OngoingThis study compares a new drug, pracytarabine, to the standard drug regorafenib in 60 people with advanced liver cancer that has stopped responding to targeted therapy and immunotherapy. The goal is to see if pracytarabine can help patients live longer. Participants receive eithe…
Phase: PHASE2, PHASE3 • Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Poop pills could clear brain fog in liver disease
Disease control OngoingThis study tests whether transplanting healthy gut bacteria from donors can improve confusion in people with advanced liver disease. Thirty participants will receive either fecal transplant capsules or a placebo. The goal is to see if this approach can safely improve thinking and…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Liver drug study pulled before it even started
Disease control TerminatedThis study aimed to see if the antibiotic rifaximin could help people with liver cirrhosis who have a mild form of brain fog called covert hepatic encephalopathy, along with bacterial overgrowth in the gut. Researchers planned to give 40 patients rifaximin for eight weeks and tes…
Phase: PHASE3 • Sponsor: MetroHealth Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Hepatitis b drug trial pulled before it started
Disease control TerminatedThis study was designed to test ARC-520, an experimental RNAi drug, in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more effectively. However, the trial…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental vaccine aims to stop liver cancer from returning
Disease control OngoingThis early-phase trial tests a cancer vaccine (IMA970A) combined with an immunotherapy drug (durvalumab) in 10 patients with early- to intermediate-stage liver cancer who have already received standard treatments. The goal is to see if the combination is safe and can help reduce …
Phase: PHASE1 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Fatty liver drug hope: semaglutide shows promise in Long-Term study
Disease control OngoingThis study looks at how well the diabetes drug semaglutide works for people with metabolic fatty liver disease (MAFLD) and liver scarring. About 70 adults will take the drug for 3 years as part of their regular care. The goal is to see if it can reduce liver fat, inflammation, an…
Sponsor: Center of target therapy • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Ice cream as medicine? study tests sweet treat for fatty liver and diabetes
Disease control OngoingThis study tests whether special ice creams made with natural sweeteners (brazzein, maltitol, erythritol, and fibers) can help control blood sugar and be easier on digestion than regular ice cream. One hundred adults with non-alcoholic fatty liver disease and type 2 diabetes will…
Phase: NA • Sponsor: Federal State Budgetary Scientific Institution • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Liver cancer patients get chemo via implantable pump in new safety trial
Disease control OngoingThis study tests a combined pump and catheter system that delivers chemotherapy directly to the liver in adults with colorectal cancer that has spread to the liver or with bile duct cancer. The main goal is to see if the device is safe. About 100 participants will have the pump i…
Phase: NA • Sponsor: Ronald DeMatteo, M.D. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for advanced tumors: drug trial targets untreated patients
Disease control OngoingThis study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Sound waves zapping liver tumours without a scalpel
Disease control OngoingThis study tests a new, non-invasive treatment called histotripsy that uses high-intensity ultrasound waves to destroy liver tumours. It works by creating tiny bubbles in the tumour that burst and break it apart, while sparing healthy tissue. The trial will enroll 60 people with …
Phase: NA • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for early liver cancer: radioembolization under the microscope
Disease control OngoingThis study looks at how well a treatment called 90Y radioembolization works for people with early-stage liver cancer. Researchers will track 200 patients in Korea to see how the tumors respond, how long patients live, and any side effects. The goal is to gather real-world data to…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug cocktail aims to fight advanced liver cancer
Disease control OngoingThis phase 3 study tests whether a combination of cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy) works better than the standard drug sorafenib for people with advanced liver cancer who haven't had prior systemic treatment. About 837 adults are taking part. …
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New targeted pill shows promise for rare bile duct cancer in small trial
Disease control OngoingThis study tests a daily pill called ivosidenib in 12 Japanese patients with advanced bile duct cancer that has an IDH1 mutation and has already been treated with other therapies. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants …
Phase: PHASE2 • Sponsor: Servier • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug cocktail aims to fight incurable liver cancer
Disease control OngoingThis phase 3 trial tests whether adding two drugs (camrelizumab and rivoceranib) to a standard liver cancer procedure (TACE) helps people with incurable liver cancer live longer without their disease getting worse. About 423 participants are randomly assigned to get either the co…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Phase: PHASE1, PHASE2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug combo shows promise for rare bile duct cancer
Disease control OngoingThis study tests a combination of two drugs, atezolizumab and derazantinib, in 27 adults with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has a specific FGFR2 gene change. The goal is to see if the combination shrinks tumors. Participants receive bo…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New program aims to protect liver patients from dangerous painkiller side effects during surgery
Disease control OngoingThis study tests a hospital program to avoid giving NSAIDs or metamizole to people with advanced chronic liver disease who need major surgery. These painkillers are risky for them because they can cause kidney damage, fluid buildup, or bleeding. The program will track how often t…
Phase: NA • Sponsor: Parc de Salut Mar • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Exercise over pills: new study tests if moving more can shrink fatty liver
Disease control OngoingThis pilot study is testing whether a 24-week program of adapted physical activity, combined with diet advice, can reduce liver fat in 115 adults with non-alcoholic fatty liver disease (NAFLD). Participants will follow personalized exercise and diet plans, and researchers will me…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Stomach sleeve without surgery shows promise for fatty liver
Disease control OngoingThis study looks at whether a non-surgical stomach reduction procedure (endoscopic sleeve gastroplasty) can improve liver health in people with obesity and advanced NASH (a severe form of fatty liver disease). Twenty adults with obesity and biopsy-confirmed NASH with advanced sca…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for Hard-to-Treat liver disease: steroid combo trial launches
Disease control ENROLLING_BY_INVITATIONThis study looks at whether adding prednisone to standard UDCA treatment helps people with primary biliary cholangitis (PBC) who also have moderate to severe interface hepatitis, a type of liver inflammation. About 244 adults will be randomly assigned to receive either UDCA alone…
Phase: PHASE2, PHASE3 • Sponsor: Han Ying • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New PET scan could help match liver transplants to right patients
Diagnosis OngoingThis study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cance…
Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
Blood test aims to outshine ultrasound for liver cancer detection
Diagnosis OngoingThis trial is testing a blood test that looks for DNA markers of liver cancer in people with liver cirrhosis, who are at high risk for developing the disease. The test is compared to standard ultrasound to see which method is better at detecting liver cancer. If the blood test pr…
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New scanner aims to spot fatty liver without needles
Diagnosis TerminatedThis study was designed to test a new thermo-acoustic imaging device that may help diagnose fatty liver disease without invasive procedures. It would have compared the device's accuracy to standard MRI scans in adults aged 18-70 with known or suspected fatty liver. However, the s…
Sponsor: Medical College of Wisconsin • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI could spot liver cancer types and predict survival without needle biopsy
Diagnosis OngoingThis study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…
Sponsor: Guangxi Medical University • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Double-Dye MRI could sharpen liver cancer detection
Diagnosis OngoingThis study tests whether using two contrast dyes during MRI can better tell apart benign and malignant liver lesions. About 100 patients with known or suspected liver growths will receive both gadoxetate disodium and gadobutrol before imaging. The goal is to see if the combinatio…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Simple blood test could spot hidden liver damage before It's too late
Diagnosis OngoingThis study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
AI spots hidden liver disease in routine scans
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether an AI system can help doctors identify patients with fatty liver disease who need specialist care. About 8,000 adults getting routine CT scans will have their images analyzed by AI to flag those at risk. The goal is to see if AI can improve detection and …
Phase: NA • Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New imaging study aims to spot liver trouble in obese kids without needles
Diagnosis ENROLLING_BY_INVITATIONThis study follows 300 children aged 9 to 14 with obesity to see if ultrasound and MRI can detect early signs of liver disease. Researchers will compare imaging markers like liver fat and stiffness with standard tests. The goal is to improve diagnosis and monitoring without invas…
Sponsor: Sahlgrenska University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
Simple blood test could spot hidden liver disease in women
Diagnosis OngoingThis study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New blood test aims to catch liver cancer recurrence early
Diagnosis OngoingThis study is testing a new blood test that looks for DNA changes to detect if liver cancer has come back or spread after surgery. Researchers at Mayo Clinic are enrolling 36 patients with early-stage liver cancer who are scheduled for surgery. The goal is to see if this test can…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Blood test boosts liver cancer detection in High-Risk patients
Diagnosis ENROLLING_BY_INVITATIONThis study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…
Phase: NA • Sponsor: Siriraj Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New MRI scan could replace painful liver biopsies for MASH patients
Diagnosis ENROLLING_BY_INVITATIONThis study aims to see if a special MRI scan can accurately detect liver scarring (fibrosis) in people with a liver condition called MASH. Researchers will compare the MRI results with standard tests like ultrasound and blood work in 50 adults. If successful, this could offer a n…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New MRI dye could sharpen liver lesion detection
Diagnosis ENROLLING_BY_INVITATIONThis study compares a new MRI contrast agent, gadopiclenol, to the standard agent, gadoxetate, for imaging liver lesions. Researchers will enroll 23 adults with chronic liver disease or known liver lesions to see if gadopiclenol provides equal or better image quality and lesion v…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Biopsy needle showdown: which tool gets the best tissue sample?
Diagnosis TerminatedThis study aimed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis. The study was planned for adults needing this procedure, but it was withdrawn …
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Blood test breakthrough could end painful liver biopsies for NASH patients
Diagnosis OngoingThis study looks at whether two blood markers, PLIN2 and RAB14, can accurately diagnose NASH (a serious liver disease) and advanced scarring, without needing a liver biopsy. Researchers will test these markers in 828 adults with NASH, type 2 diabetes, or obesity. If successful, t…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
One Breath-Hold MRI could replace liver biopsies for NASH
Diagnosis OngoingThis study tests a new MRI technique that measures liver fat, fibrosis, and inflammation in a single 14-second breath-hold, without needles or contrast dye. Researchers will scan 120 people with fatty liver disease (60 with simple steatosis and 60 with NASH) and compare results t…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
New biomarkers may sharpen cancer diagnosis in bile duct blockages
Diagnosis OngoingThis study looks at whether measuring certain substances in bile and blood can more accurately diagnose cancer in people with bile duct blockages. Researchers will compare these new tests with standard methods in 500 adults undergoing a procedure called ERCP. The goal is to find …
Sponsor: AdventHealth • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New blood test could spot liver cancer sooner
Diagnosis ENROLLING_BY_INVITATIONThis study is testing whether a new blood test score, called GAAD, can detect liver cancer earlier in people with chronic liver disease. The GAAD score combines a person's gender, age, and two blood markers (AFP and PIVKA-II). Researchers will compare the GAAD score to standard u…
Phase: NA • Sponsor: Mahidol University • Aim: Diagnosis
Last updated Jun 27, 2026 08:08 UTC
-
Training the immune system to hunt down leftover liver cancer cells
Prevention OngoingThis phase 2 trial tests whether a vaccine made from a patient's own dendritic cells — immune cells trained to recognize liver cancer — can prevent the cancer from returning after surgical removal of the tumor. About 74 adults with a high risk of recurrence will receive the vacci…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
Peer-led prevention: can gancheros help stop HIV, hepatitis c, and overdose in NYC?
Prevention OngoingThis pilot trial tests whether training Gancheros—people who provide injection services in exchange for money or drugs—can lower HIV, hepatitis C, and overdose risks among migrant Puerto Rican people who inject drugs in New York City. Gancheros will attend six sessions on prevent…
Phase: NA • Sponsor: North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI) • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
New stent study aims to ease jaundice in cancer patients
Symptom relief TerminatedThis study looks at whether a special stent (Hot AXIOS) can improve quality of life for people with bile duct blockages caused by cancer, when standard drainage fails. About 162 adults will receive the stent during an endoscopic procedure. The main goal is to see if jaundice symp…
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a smartwatch and nutrition coaching ease cirrhosis symptoms?
Symptom relief OngoingThis study tests a home monitoring program called LiverWatch for people with advanced liver disease (cirrhosis). Participants get a Fitbit, personalized nutrition advice, and weekly check-ins to boost activity and manage symptoms. The goal is to see if this approach improves qual…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Could a simple hat make jaundice treatment kinder for newborns?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a special hat with built-in goggles can make phototherapy more comfortable for full-term newborns with jaundice, compared to standard eye patches. Researchers will measure the babies' comfort levels, bilirubin changes, treatment duration, and parental sat…
Phase: NA • Sponsor: Karamanoğlu Mehmetbey University • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Could a personal coach at home boost energy for cancer patients?
Symptom relief OngoingThis study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…
Phase: NA • Sponsor: UNICANCER • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Can an epidural pump beat IV painkillers after liver surgery?
Symptom relief OngoingThis trial compares two ways to control pain after open liver surgery: an epidural pump that delivers pain medicine near the spine, versus a standard IV pump. About 230 adults having elective open liver resection will be randomly assigned to one method. The goal is to see which a…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
New drug shows promise for relieving severe itch in liver disease
Symptom relief OngoingThis study tests the long-term safety of linerixibat, a drug for severe itching caused by primary biliary cholangitis (PBC). All 242 participants receive the drug openly. The goal is to see if it remains safe over time and improves quality of life.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study compares two drainage techniques to ease jaundice in advanced cancer patients
Symptom relief TerminatedThis study compares two minimally invasive procedures to drain blocked bile ducts in patients with incurable cancer. One method drains the bile duct into the intestine, the other drains the gallbladder into the stomach. The goal is to see which approach causes fewer complications…
Phase: NA • Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Magic mushroom compound tested for cancer anxiety
Symptom relief OngoingThis early-stage study tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can reduce depression and anxiety in people with advanced pancreatic, biliary, or other gastrointestinal cancers. The study enrolls 24 adults aged 19-85 with stage IV or in…
Phase: PHASE1 • Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New study tests safer bile duct drainage for cancer patients
Symptom relief TerminatedThis study compares two procedures to relieve bile duct blockage caused by cancer. About 120 patients with pancreatic or bile duct cancer will be randomly assigned to get either a newer ultrasound-guided drainage or the standard ERCP procedure. The goal is to see which method has…
Phase: NA • Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can one weekly workout beat fatty liver? new study tests the ideal exercise frequency
Symptom relief OngoingThis study looks at whether exercising once a week or three times a week is better at reducing liver fat in adults who are centrally obese and have non-alcoholic fatty liver disease (NAFLD). Three hundred Chinese adults aged 18-69 will be assigned to either a once-weekly or thric…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Tapping away the fear: EFT tested in rare bile duct cancer
Symptom relief OngoingThis early-phase study looks at whether Emotional Freedom Techniques (EFT) — a practice that combines tapping on acupressure points with counseling — can reduce anxiety, depression, pain, and insomnia in people with cholangiocarcinoma, a rare and aggressive bile duct cancer. Four…
Phase: EARLY_PHASE1 • Sponsor: Soul Medicine Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Pre-Surgery boot camp for liver cancer patients shows promise
Symptom relief ENROLLING_BY_INVITATIONThis study tests a nurse-led program that starts at least a week before liver cancer surgery. It includes exercise, nutrition advice, mental support, and help quitting smoking or drinking. The goal is to see if this program helps patients stay stronger, feel less anxious, and hav…
Phase: NA • Sponsor: Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Can a phone app help people with HIV beat fatty liver disease?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a mobile app-based nutritional program can help people living with HIV and fatty liver disease lose at least 5% of their body weight in 6 months. Participants are randomly assigned to use the app or receive standard lifestyle advice. The goal is to find a…
Phase: NA • Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could early palliative care before cancer surgery improve quality of life?
Symptom relief OngoingThis study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
FitBit and app aim to keep cancer surgery patients out of the hospital
Symptom relief OngoingThis study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Cured of hepatitis c? this study follows patients for 10 years to see what happens next
Knowledge-focused OngoingThis study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …
Phase: PHASE4 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
HIV and hidden health risks: a major study probes the link
Knowledge-focused OngoingThis study compares over 1,500 people living with HIV to a similar group from the general population to see if conditions like heart disease, COPD, and liver disease are more common or develop faster in those with HIV. Using detailed scans and tests, researchers will measure the …
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immune cells predict herpesvirus danger in transplant patients?
Knowledge-focused OngoingThis study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ re…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Cancer tissue bank study aims to unlock new treatment clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can smarter surgical tools cut liver surgery risks?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks back at the records of about 800 adults who had minimally invasive liver surgery (laparoscopic, robotic, or hybrid) at specialized Italian centers. The goal is to see how the choice of surgical tools and techniques for cutting liver tissue relates to the risk of …
Sponsor: University of Molise • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Liver study tests how body handles experimental drug
Knowledge-focused OngoingThis early-stage study looks at how the experimental drug nemtabrutinib is processed in people with moderate liver impairment compared to healthy volunteers. About 32 adults will receive a single oral dose, and researchers will measure drug levels in the blood over time. The goal…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can hormone therapy change liver health? a new study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at liver health in transgender people who are on gender-affirming hormone therapy (GAHT). It compares those who have been on hormones for more than six months with those on them for less time. Researchers will measure liver function through blood tests and a spec…
Sponsor: Corey DeStefano • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New study analyzes Odevixibat's impact on rare liver disease outcomes
Knowledge-focused OngoingThis study looks at a rare liver disease called PFIC, which causes severe itching and liver damage. Researchers compare patients who took the drug odevixibat to those who did not, using data from past studies and a patient registry. The goal is to see if odevixibat helps avoid li…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Liver scan changes may foretell deadly complications
Knowledge-focused OngoingThis study looks at medical records from 10,000 adults with MASLD or MASH, a common liver condition. Researchers will check if changes in liver stiffness, measured by a non-invasive scan called FibroScan, are linked to future serious liver problems like cirrhosis, liver cancer, o…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Veterans study aims to boost colon and liver cancer screening
Knowledge-focused ENROLLING_BY_INVITATIONThis study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can tracking hospital care for liver patients reduce repeat admissions?
Knowledge-focused OngoingThis study follows about 400 adults with liver cirrhosis admitted to internal medicine wards across Italy. Researchers will track how doctors manage hepatic encephalopathy—a brain complication of liver disease—during hospitalization and after discharge. The goal is to identify pr…
Sponsor: Fadoi Foundation, Italy • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
New fatty liver drug tested in healthy volunteers – no cure expected
Knowledge-focused OngoingThis early-stage study tests a single dose of the experimental drug efimosfermin alfa in 30 healthy adults of Chinese, Japanese, and White/European ancestry. The goal is to check safety, how the body processes the drug, and immune reactions. Participants will not receive any trea…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Hidden costs of caregiving: new study tracks financial toxicity in cirrhosis families
Knowledge-focused OngoingThis observational study looks at the financial and social challenges faced by informal caregivers of people with cirrhosis. Researchers will measure out-of-pocket costs, lost work time, and financial distress using surveys. The goal is to understand how these burdens affect care…
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Unapproved device tested in early trial
Knowledge-focused OngoingThis trial is testing a medical device that has not been approved or cleared by the U.S. FDA. The study is small and early-stage, focused on understanding how the device works and whether it is safe. No results are available yet, and the device is not ready for widespread use.
Phase: NA • Sponsor: C. R. Bard • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Blood markers could transform liver cancer surveillance
Knowledge-focused OngoingThis study follows people with liver cancer who are scheduled for surgery, measuring tiny molecules called microRNAs in their blood before and after the operation. The goal is to find patterns that could signal whether the cancer has come back. Researchers will also look at gut b…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Blood test and AI could spot liver cancer early, saving lives
Knowledge-focused OngoingThis study follows 2,002 people at high risk for liver cancer to find better ways to detect it early. Researchers are testing a panel of blood-based miRNA markers, gut microbiome changes, and MRI-based AI algorithms to predict who develops the disease. The goal is to improve on c…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Blood type no barrier? study tests liver transplant success across ABO barriers
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks back at 371 adults who received a living donor liver transplant for hepatocellular carcinoma (a type of liver cancer) to see whether receiving a liver from a donor with an incompatible blood type affects long-term survival or cancer recurrence. Researchers compar…
Sponsor: Seoung Hoon Kim • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Draining the bile duct: does it improve daily life for cancer patients?
Knowledge-focused OngoingThis study tracks quality of life in 118 people with cancer who have a blocked bile duct and undergo a drainage procedure. Participants fill out a questionnaire before the procedure and again at 4 weeks, 12 weeks, and 6 months after. The goal is to see whether a drainage catheter…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Scientists hunt for clues in body fluids to predict liver failure outcomes
Knowledge-focused OngoingThis study aims to find biological markers in blood, urine, stool, and breath that can predict how patients with acute liver injury or failure will fare. Researchers will collect samples daily for up to seven days from 200 participants, and a small group will also undergo MRI sca…
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Taiwan launches genetic map for bile duct cancer
Knowledge-focused OngoingThis study collects tumor tissue from 480 people with advanced biliary tract cancer in Taiwan to analyze their genetic makeup. The goal is to create a detailed map of genetic changes in this cancer, which could help identify potential targeted therapies. Participants are already …
Sponsor: National Health Research Institutes, Taiwan • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
10-Year hepatitis study aims to unlock secrets of liver disease
Knowledge-focused OngoingThis study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive korean study maps the overlap of heart, kidney, and metabolic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No …
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists probe immune cell exhaustion in hepatitis b
Knowledge-focused OngoingThis study looks at how chronic hepatitis B virus (HBV) infection affects natural killer (NK) cells, which are key immune cells that fight infections. Researchers will collect blood samples from 80 people with HBV and compare them to healthy donors. The goal is to understand why …
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive UK study tracks cancer after organ transplants
Knowledge-focused OngoingThis study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…
Sponsor: University of Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Fatty liver study pulled before it began
Knowledge-focused TerminatedThis study was designed to look at how tiny energy-producing parts of cells (mitochondria) in the liver might be linked to fatty liver disease in people with obesity who were scheduled for weight-loss surgery. Researchers planned to take small liver samples during surgery to stud…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Simple blood test may spot hidden liver trouble in colitis patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether two blood markers, zonulin and LBP, can help detect liver damage in people with both ulcerative colitis (UC) and fatty liver disease. Researchers will measure these markers and use a special ultrasound to check liver stiffness in 100 adults with UC who…
Sponsor: University Hospital Dubrava • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Hepatitis b breakthrough? study checks if bepirovirsen response lasts
Knowledge-focused OngoingThis study follows about 360 people with chronic hepatitis B who had a good response to the experimental drug bepirovirsen in earlier trials. No new drug is given; researchers simply monitor whether the response lasts over time. Participants may or may not continue standard antiv…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Egyptian study pits two liver cancer drug combos Head-to-Head
Knowledge-focused OngoingThis study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …
Sponsor: Sohag Oncology Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Ultrasound for all: 9,000-Patient trial tests quicker hospital stays
Knowledge-focused OngoingThis study looks at whether using a simple bedside ultrasound exam on all hospitalized patients can shorten their hospital stay. Researchers will check the heart, kidneys, liver, and lungs for common problems. The goal is to see if this routine check helps doctors make faster dec…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver transplant study tests best way to manage fluids during surgery
Knowledge-focused OngoingThis pilot study compares two approaches to giving fluids during liver transplant surgery: a restrictive strategy that removes some blood early and returns it later, versus a liberal strategy that keeps blood flow high. The goal is to see if a larger study is possible by checking…
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
COVID-19's hidden toll on liver cancer patients revealed
Knowledge-focused OngoingThis study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can the liver heal itself? new study tracks unexpected recovery in cirrhosis patients
Knowledge-focused OngoingThis study looks at 300 patients with advanced liver scarring (cirrhosis) caused by hepatitis B or alcohol who have shown signs of getting better. Researchers want to understand what predicts this improvement and how long it lasts. The goal is to create clearer guidelines for whe…
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a smartwatch help manage a rare liver disease? stanford study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study at Stanford University is testing whether wearable devices like smartwatches can help measure fatigue, sleep, and daily activity in people with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will compare data from the wearables with patient que…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Pandemic's hidden toll: frailty rises in liver transplant hopefuls
Knowledge-focused OngoingThis study examines whether the COVID-19 pandemic increased frailty and muscle loss (sarcopenia) in people waiting for a liver transplant. Researchers will compare data from 208 patients assessed before and during the pandemic. The goal is to understand how the pandemic affected …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New screening tool aims to catch hidden need for palliative care in hospitals
Knowledge-focused OngoingThis study tests a questionnaire called NECPAL to see if it can spot patients with serious long-term illnesses like cancer, heart failure, or kidney disease who might benefit from palliative care. Researchers will check 200 adults in the hospital or day clinic to see how many are…
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Frailty check could predict chemo danger for seniors
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…
Sponsor: Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Liver's Fat-Burning secrets revealed in sleeve gastrectomy study
Knowledge-focused OngoingThis study looks at how the liver burns fat and makes sugar in people with NASH (a serious liver disease linked to obesity) who are planning to have weight-loss surgery. Researchers will use special scans to measure liver function before and after surgery in 30 adults. The goal i…
Phase: NA • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study tracks blood sugar in liver disease patients on common drug
Knowledge-focused OngoingThis study looks at how a type of medication called PPAR agonists affects blood sugar levels in 30 adults with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will measure changes in blood sugar and other metabolic markers over three months. The goal is to…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Veteran peers lead fight against opioid overdose
Knowledge-focused OngoingThis study tests a program where veteran peer workers provide education, healthcare navigation, and social support to 150 veterans with opioid use disorder who are not connected to VA healthcare. The goal is to reduce risky behaviors related to overdose and HIV/HCV infection. Res…
Phase: NA • Sponsor: New York University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …
Phase: NA • Sponsor: Université de Montréal • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
AI tool aims to predict where liver cancer spreads next
Knowledge-focused OngoingThis study is testing a machine learning tool that predicts the risk of liver cancer spreading to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread are being followed to see if the tool helps doctors make better decisions about monitoring. The tool gi…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can a special PET scan unlock a new way to treat Hard-to-Treat upper GI cancers?
Knowledge-focused OngoingThis study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…
Phase: PHASE2 • Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
One shot enough? thai kids' hepatitis a immunity tested years later
Knowledge-focused OngoingThis study follows 60 healthy Thai children and teens who received a single dose of a live-attenuated hepatitis A vaccine about a year ago. Researchers want to see how many still have protective antibodies and at what levels. The goal is to understand long-term immunity and help …
Sponsor: Chiang Mai University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
AI messages aim to curb drinking in cancer survivors
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether AI-generated messages can change how cancer survivors think about alcohol and cancer risk. About 850 adults who have had certain cancers and currently drink alcohol will view different messages. Researchers will measure changes in their beliefs about canc…
Phase: NA • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Keyhole vs open surgery: which is better for rare pancreatic cancer?
Knowledge-focused ENROLLING_BY_INVITATIONThis study compares two surgical techniques—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called nonpancreatic periampullary adenocarcinoma. Researchers will track how long patients stay in the hospital after surgery, as well as survival rat…
Phase: NA • Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Why are young people getting cancer? a massive study aims to find out.
Knowledge-focused TerminatedThis research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Can scans tell who needs surgery after liver tumor shrinks?
Knowledge-focused OngoingThis study looks back at 500 people with liver cancer that could not be removed at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers want to see if using scans and patient data can help deci…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Porphyria biomarker hunt could transform patient monitoring
Knowledge-focused OngoingThis study aims to find new biological markers (biomarkers) that can show how active acute porphyria is in the body and how well treatments are working. Researchers will study 50 people with confirmed acute porphyria to measure gene activity related to heme production and stress …
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry to monitor hepatitis b vaccine safety in pregnancy
Knowledge-focused TerminatedThis study was designed to collect information on pregnancy and baby outcomes in women who received the PREHEVBRIO hepatitis B vaccine around the time of conception or during pregnancy. The goal was to watch for any safety concerns, such as miscarriage or birth defects. However, …
Sponsor: VBI Vaccines Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Amino acid infusion study aims to unlock fatty liver secrets
Knowledge-focused OngoingThis study looks at how amino acids trigger the liver to release hormones in healthy people and those with non-alcoholic fatty liver disease. Researchers will give amino acid infusions with or without a drug that blocks natural hormone production. By comparing the results, they h…
Phase: NA • Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Tiny sensors could revolutionize jaundice treatment for newborns
Knowledge-focused OngoingThis study tests a new wireless sensor that continuously measures the light dose babies receive during phototherapy for jaundice. Currently, doctors check light levels only once a day with a handheld device, which can be inaccurate. The sensor aims to provide real-time data to en…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Liver cirrhosis study looks at cholesterol marker levels
Knowledge-focused TerminatedThis study measures levels of a substance called 4beta-hydroxycholesterol in the blood of people with liver cirrhosis. It compares these levels to those in people with pneumonia, Crohn's disease, or ulcerative colitis. The goal is to understand how cirrhosis and certain medicatio…
Sponsor: University of Oulu • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Personalized blood test aims to track stomach and colon cancer spread
Knowledge-focused TerminatedThis study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Prison hepatitis c study pulled before it began
Knowledge-focused TerminatedThis study planned to see if faster testing and treatment for hepatitis C could be given to inmates right when they enter prison. The goal was to start medication sooner to reduce the spread of the virus. However, the study was withdrawn and no one took part.
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
One-stop screening clinic aims to catch hidden diabetes complications early
Knowledge-focused OngoingThis study is testing a new type of clinic that screens people with prediabetes and type 2 diabetes for several hidden health problems at the same time, including fatty liver disease, sleep apnea, and heart failure. The goal is to see how common these undiagnosed conditions are a…
Sponsor: University of Liverpool • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
240 cirrhosis patients studied to uncover hidden clot risks
Knowledge-focused OngoingThis study looks at 240 adults with liver cirrhosis to learn more about a common complication called portal vein thrombosis (a blood clot in the liver's main vein). Researchers will use ultrasound and CT scans to find clots and track their patterns. The goal is to identify which …
Sponsor: Elham Ahmed Hassan • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study aims to detect liver damage without needles
Knowledge-focused OngoingThis study looks at whether simple blood tests and special scans can detect liver scarring in people with urea cycle disorders. Researchers will enroll 62 participants across five U.S. centers. The goal is to find noninvasive ways to monitor liver health, avoiding the need for li…
Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Gut bacteria may forecast surgery risks in pancreatic cancer patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study is collecting saliva, stool, blood, bile, and tumor samples from 200 people undergoing surgery for pancreatic or related cancers. Researchers want to see if the types of bacteria in these samples can help predict who will have complications after surgery and how the ca…
Sponsor: St. Antonius Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Early warning probe could save lives after pancreatic surgery
Knowledge-focused OngoingThis study tests a new monitoring method for patients who have had pancreatic surgery. After surgery, a thin probe is placed near the surgical connection to measure chemicals that may signal a leak before symptoms appear. Half of the 201 participants will receive this monitoring …
Phase: NA • Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New MRI scan could predict liver cancer in NASH patients
Knowledge-focused OngoingThis study tests a new, longer MRI scan that measures liver stiffness and viscosity to see if it can identify NASH patients at higher risk for liver cancer. About 35 adults with NASH and early-stage liver scarring will participate. The goal is to improve early detection, not to t…
Sponsor: Natalie Torok • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a computer predict liver cancer before it strikes?
Knowledge-focused OngoingThis study checks if a computer model called LIRIC can accurately predict who will develop liver cancer using electronic health records. Researchers will track 6 million adults aged 40 and older without a history of liver cancer to see how well the model works. The goal is to imp…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a new model forecast liver failure survival?
Knowledge-focused OngoingThis study looks at 2000 patients with acute-on-chronic liver failure caused by hepatitis B. Researchers will collect blood samples and medical data to build a model that predicts survival and complications at different time points. The goal is to give doctors a better way to est…
Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver disease growth study cancelled before it began
Knowledge-focused TerminatedThis study planned to test a growth factor medicine (Increlex) in children aged 4-18 with chronic liver disease and short stature. The goal was to see if it could improve growth and quality of life. However, the study was withdrawn before any participants were enrolled, so no res…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Simple ultrasound could spot liver trouble in heart kids
Knowledge-focused OngoingThis study follows 50 children with single-ventricle heart disease who have had the Fontan operation. Researchers use a special ultrasound to measure liver stiffness, which may indicate congestion and predict future complications like liver disease. The goal is to find a noninvas…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
100,000 families join landmark study on parental exposures and child health
Knowledge-focused OngoingThis study follows 100,000 Chinese families from before pregnancy through the child's teenage years. Researchers collect health data, biospecimens, and environmental information to understand how parents' exposures affect pregnancy outcomes and child development. The goal is to f…
Sponsor: National Research Institute for Family Planning, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can a dental visit help liver patients?
Knowledge-focused OngoingThis study looks at whether offering dental exams and cleanings to people with cirrhosis can improve their oral health and overall well-being. Researchers will also ask participants about barriers to getting dental care. About 100 adults with confirmed cirrhosis will take part, a…
Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Fatty liver study pulled before it began: new imaging test never tested
Knowledge-focused TerminatedThis pilot study was designed to see if a special MRI technique called field-cycling imaging could tell the difference between simple fatty liver and more serious liver scarring (fibrosis) in adults with non-alcoholic fatty liver disease (NAFLD). The goal was to find a non-invasi…
Phase: NA • Sponsor: NHS Grampian • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Major study aims to spare patients painful liver biopsies
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1,689 adults with fatty liver disease (MASLD) or MASLD with increased alcohol intake (MetALD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression. The goal is to reduce the need for liver biopsies in future research and …
Sponsor: HRI-MAIL-NIT • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Hormone clues in cirrhosis and low blood pressure study withdrawn
Knowledge-focused TerminatedThis study was designed to measure estrogen and testosterone levels in men with liver cirrhosis who also have low blood pressure, compared to those with cirrhosis but normal blood pressure. The goal was to understand why low blood pressure occurs in cirrhosis. However, the study …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Liver tumor treatment study halted before it began
Knowledge-focused TerminatedThis study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Tumor DNA study aims to unlock secrets of drug resistance
Knowledge-focused OngoingThis study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Stomach ultrasound could spot liver trouble early
Knowledge-focused OngoingThis study looks at whether a new ultrasound technique done through the stomach (endoscopic ultrasound elastography) can better predict serious liver problems in people with chronic liver disease. Researchers will measure liver and spleen stiffness in 50 patients and compare resu…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Researchers watch and learn: liver transplant outcomes for cancer patients
Knowledge-focused OngoingThis study is a registry that follows 1,000 adults with liver cancer who receive a liver transplant. Researchers will track how long patients live without their cancer coming back and overall survival. The goal is to learn more about outcomes and what predicts recurrence, not to …
Sponsor: Federico Aucejo • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
500,000-Patient study aims to unlock secrets of chronic liver disease
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will follow up to 500,000 adults with chronic liver disease or cirrhosis to understand how the disease progresses and how treatments are used in everyday practice. Researchers will collect data from medical records and patient reports to improve care and …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Massive pancreatic surgery registry launches to improve patient care
Knowledge-focused OngoingThis registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Cheaper brain monitoring method tested in liver transplants
Knowledge-focused OngoingThis study compares two non-invasive methods for monitoring brain blood flow during liver transplant surgery: carotid Doppler ultrasound and near-infrared spectroscopy (NIRS). The goal is to see if the simpler, cheaper ultrasound can replace the more expensive NIRS. The study inv…
Sponsor: Inonu University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Hope for hepatitis delta patients: study seeks to end lifelong treatment
Knowledge-focused OngoingThis study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predic…
Phase: NA • Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Doctor's digital nudge: could a computer prompt boost liver cancer detection?
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether an automatic reminder in the electronic health record can increase the number of cirrhosis patients who get screened for liver cancer (hepatocellular carcinoma). The reminder prompts doctors to order a liver ultrasound when they see a patient with cirrhos…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
3D-Printed tumors could revolutionize liver cancer drug matching
Knowledge-focused OngoingThis study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New tool aims to predict brain risks after liver shunt procedure
Knowledge-focused OngoingThis study looks back at medical records of 624 adults with liver cirrhosis who had a procedure called TIPS to relieve pressure in the liver. The goal is to create a simple tool that helps doctors predict which patients are at high risk for a brain complication called hepatic enc…
Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Fatty liver disease: what do doctors and patients really think?
Knowledge-focused OngoingThis study uses interviews and questionnaires to learn how primary care doctors and Hispanic patients think about non-alcoholic fatty liver disease (NAFLD). Researchers want to understand what doctors know about diagnosing and treating NAFLD, and how cultural factors affect patie…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Hepatitis b drug holiday: can stopping treatment lead to a cure?
Knowledge-focused OngoingThis study follows 54 people with chronic hepatitis B who stop taking their antiviral medication after at least three years. Researchers will closely monitor their immune system and virus levels to see what happens during a flare. The goal is to learn whether a controlled flare m…
Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Liver shunt study tracks Real-World outcomes for 852 patients
Knowledge-focused OngoingThis study follows 852 adults with liver cirrhosis who are scheduled for a TIPS procedure, a shunt placed in the liver to relieve dangerous high blood pressure. Researchers will collect information from standard medical care over 5 years to learn how to best use TIPS and reduce c…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New scan could help spare healthy liver during cancer radiation
Knowledge-focused OngoingThis pilot study tests a special SPECT imaging scan called hepatobiliary scintigraphy to measure how radiotherapy changes liver function. Twenty adults with liver cancer will get the scan before and after radiation. The goal is to see if this method can show which parts of the li…
Sponsor: Royal North Shore Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Electric shocks + chemo: new hope for liver tumors?
Knowledge-focused OngoingThis study is a registry that collects information on how well electrochemotherapy (ECT) works for people with liver cancer. ECT uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The study will follow 250 adults with primary or secondary l…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New decision aid aims to boost liver cancer screening in veterans
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a new decision aid tool (OASIS) that helps VA hospitals choose the best strategies to improve screening for liver cancer in patients with cirrhosis. Over 8,000 veterans and clinicians at multiple VA medical centers will participate. The goal is to see if the tool…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New scan reveals hidden metabolic clues in fatty liver disease
Knowledge-focused OngoingThis study uses advanced full-body PET scans to see how the body handles sugar and amino acids in healthy people and those with non-alcoholic fatty liver disease (NAFLD). About 36 adults aged 18-70 will receive a radioactive tracer by mouth or IV and have scans to track nutrient …
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Phase: NA • Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
AI could help doctors personalize treatment for autoimmune hepatitis
Knowledge-focused OngoingThis study uses artificial intelligence to analyze data from 5,000 people with autoimmune hepatitis. The goal is to create a computer model that can predict which patients will respond well to standard therapy within 6 to 12 months. By identifying these patterns early, doctors ma…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Could a hidden liver condition cause POTS? new study aims to find out
Knowledge-focused OngoingThis study looks at whether people with Postural Orthostatic Tachycardia Syndrome (POTS) might also have a rare condition called acute hepatic porphyria (AHP), which can cause similar symptoms like rapid heart rate and abdominal pain. Researchers will test 70 adults with POTS usi…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New registry aims to improve bile duct stone removal
Knowledge-focused OngoingThis study is a registry that collects information from patients who have a procedure called percutaneous cholangiopancreatoscopy (PCPS). During PCPS, doctors use a tiny camera to see inside the bile ducts and remove stones or take tissue samples. The goal is to learn how well th…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
HIV and fatty liver: a hidden risk revealed?
Knowledge-focused OngoingThis study looks at how often fatty liver disease occurs in people living with HIV. Researchers will measure liver fat in 1,250 adults with HIV who are on stable treatment. The goal is to understand the true scale of this liver condition in this group, which has been largely over…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Scientists probe immune secrets of chronic hepatitis b
Knowledge-focused OngoingThis study looks at how the immune system behaves in people with chronic hepatitis B. Researchers are measuring different immune cells and signals to understand why some people control the virus better than others. 201 adults already enrolled in a larger hepatitis B study are pro…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Immune clues in hepatitis b: study aims to unlock better treatment
Knowledge-focused OngoingThis study looks at how the immune system responds to chronic hepatitis B infection. Researchers will analyze blood samples from 40 adults already enrolled in larger treatment trials. The goal is to understand why some people respond better to therapy and how the disease progress…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Cancer tissue bank aims to fuel future discoveries
Knowledge-focused OngoingThis study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Simple nudge: mailed reminders and navigators may catch liver cancer earlier
Knowledge-focused OngoingThis study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepat…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
1,200-Patient study aims to predict liver failure risks
Knowledge-focused OngoingThis observational study follows 1,222 adults with liver cirrhosis to understand why some develop serious complications like fluid buildup or bleeding. Participants have check-ups every six months, including questionnaires, physical exams, and imaging. The goal is to build better…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Rare bile duct cysts: how often do they turn into cancer?
Knowledge-focused ENROLLING_BY_INVITATIONThis study reviews medical records of 300 people diagnosed with choledochal cysts (bile duct cysts) between 2000 and 2020 in Western hospitals. The goal is to find out how often these cysts lead to bile duct cancer and what factors increase that risk. By analyzing symptoms, treat…
Sponsor: María Teresa Moreno Asencio • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
120,000-Person study hopes to crack the code of chronic illness
Knowledge-focused TerminatedThis observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New test may reveal hidden cancer after liver ablation
Knowledge-focused OngoingThis study looks at tissue from liver tumors that were destroyed using heat or cold (ablation). The goal is to see if a special test on that tissue can tell whether the treatment fully killed the cancer, which standard CT scans cannot always do. About 150 people with liver cancer…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Diabetes and liver danger: new study follows 317 patients to uncover hidden risks
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 317 adults with type 2 diabetes who were first examined between 2019 and 2023. Researchers will repeat advanced liver scans, blood tests, and body composition measurements to see how liver fat and scarring change over time. The goal is to find out who is most a…
Sponsor: Linkoeping University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Real-World data shows promise for lenvatinib in advanced liver cancer
Knowledge-focused OngoingThis study looked back at medical records from 800 patients with unresectable liver cancer who were treated with lenvatinib-based therapy at six hospitals. Researchers analyzed how long patients survived, how well the cancer responded, and any side effects. The goal is to better …
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
HT-1 drug study in china withdrawn before starting
Knowledge-focused TerminatedThis study was designed to observe how patients with hereditary tyrosinemia type 1 (HT-1) in China respond to nitisinone treatment in everyday medical practice. It planned to track serious health events like liver problems or death. However, the study was withdrawn before enrolli…
Sponsor: Swedish Orphan Biovitrum • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists probe body tissue to unlock secrets of weight loss surgery
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand how bariatric surgery affects the body's tissues, like fat, muscle, and liver, and how it improves insulin sensitivity. Researchers will collect tissue and blood samples from 500 adults undergoing surgery or other procedures. The goal is to learn the…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Should liver cancer patients get surgery after drugs work? new study aims to find out
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at people with liver cancer that was too large or spread out to remove with surgery, but then completely disappeared after drug treatment. Researchers want to see if having surgery after the drugs work helps people live longer compared to just watching and waitin…
Sponsor: Fujian Provincial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Scientists dive deep into fatty liver to find key clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at liver tissue from 45 adults with nonalcoholic fatty liver disease (NAFLD) to identify which fats and proteins are present and how they change as the disease gets worse. Participants are 18–65 years old and scheduled for abdominal or bariatric surgery. The goal…
Sponsor: Vanderbilt University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Can MRI and ultrasound spot fatty liver in kids without a needle?
Knowledge-focused OngoingThis study tests whether MRI and ultrasound can accurately measure liver fat in children aged 10-14, both those with obesity and those at a healthy weight. Researchers will check if the scans are reliable and easy to perform. The goal is to develop a non-invasive tool to diagnose…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New study aims to uncover what cirrhosis patients really need
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at the quality of life, disease knowledge, and nursing needs of 150 adults with liver cirrhosis who visit the outpatient clinic at Landspitali University Hospital in Iceland. Participants will fill out three questionnaires and give a blood sample. The goal is to …
Sponsor: Landspitali University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Can new blood and imaging tests predict colon cancer liver spread?
Knowledge-focused OngoingThis pilot study aims to develop new ways to diagnose colon cancer and predict if it will spread to the liver. Researchers will collect blood and liver tissue samples from 51 patients undergoing surgery for colon cancer or benign colon growths. The goal is to find biomarkers that…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
10,000 flemish adults to be screened for silent liver disease
Knowledge-focused OngoingThis study aims to find out how common non-alcoholic fatty liver disease (NAFLD) is among adults in Flanders, Belgium. Researchers will screen 10,000 people at their general practitioner's office using questionnaires and quality-of-life surveys. The goal is to gather data on dise…
Phase: NA • Sponsor: Hasselt University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
New MRI scan could spot liver damage without a needle
Knowledge-focused OngoingThis study is testing whether a special MRI scan can accurately measure the severity of alcoholic liver disease without needing a biopsy. Researchers will scan 20 adults with the condition to look for imaging markers that reflect liver damage. The goal is to develop a non-invasiv…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC